Free Trial

Precipio 11/6/2024 Earnings Report

Precipio logo
$5.27 +0.12 (+2.33%)
As of 03:48 PM Eastern

Precipio EPS Results

Actual EPS
-$0.42
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Precipio Revenue Results

Actual Revenue
$5.21 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Precipio Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Remove Ads

Precipio Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Precipio Reports Positive Q4 Financial Results
See More Precipio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precipio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precipio and other key companies, straight to your email.

About Precipio

Precipio (NASDAQ:PRPO), a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

View Precipio Profile

More Earnings Resources from MarketBeat